Raymond James Upgrades Dianthus Therapeutics to Strong Buy, Raises Price Target to $123
Benzinga Newsdesk 7 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Raymond James analyst Steven Seedhouse upgrades Dianthus Therapeutics (NASDAQ:DNTH) from Outperform to Strong Buy and raises the price target from $63 to $123.
Raymond James analyst Steven Seedhouse upgrades Dianthus Therapeutics (NASDAQ:DNTH) from Outperform to Strong Buy and raises the price target from $63 to $123.